Bayer Media Event, Thursday October 16, 2025 // 13:00 – 17:10 CET

Transforming the Future
of Prostate Cancer Care

We are delighted to host an exclusive media event at Bayer’s global pharmaceutical headquarters in Berlin, ahead of this year’s European Society for Medical Oncology (ESMO) Congress, taking place in the city between 17-21 October 2025. This in-person event will offer comprehensive insights into the latest advancements in prostate cancer care. Come and discover how Bayer’s patient-centric approach is shaping the future of treatment and improving outcomes across the disease spectrum. The session will also explore the critical role of shared decision-making in improving the patient experience and treatment outcomes. Attendees will benefit from a live Q&A with leading oncology and radiology experts and a guided tour of Bayer’s state-of-the-art radiology lab. Following the event, there will be the opportunity for in-depth, one-on-one interviews with our panelists.

Please note: the event will be held under embargo.

• Data and information included in accepted abstracts is under embargo until the relevant embargo release date.

Thanks for your interest! Registration is now closed.

About Bayer

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. Prostate cancer is the second most commonly diagnosed cancer in men and a key area of focus for Bayer. The company’s franchise includes two products on the market (Nubeqa™ and Xofigo™) and several compounds in development. Bayer is focused on addressing the unique needs of patients with prostate cancer, providing treatments that extend their lives throughout the different stages of the disease and allowing them to continue with their everyday activities, so that patients can live longer, better lives.

Forward-Looking Statements

This event may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.